L
LEGEND BIOTECH CORP
NASDAQ: LEGN (Legend Biotech Corporation)
最近更新时间: 1小时之前18.97
1.22 (6.87%)
| 前收盘价格 | 17.75 |
| 收盘价格 | 17.81 |
| 成交量 | 1,820,280 |
| 平均成交量 (3个月) | 2,519,893 |
| 市值 | 3,503,560,960 |
| 预期市盈率 (P/E Forward) | 47.85 |
| 价格/销量 (P/S) | 3.59 |
| 股市价格/股市净资产 (P/B) | 3.24 |
| 52周波幅 | |
| 利润日期 | 10 Mar 2026 |
| 营业毛利率 | -29.95% |
| 营业利益率 (TTM) | -25.97% |
| 稀释每股收益 (EPS TTM) | -1.18 |
| 季度收入增长率 (YOY) | 107.50% |
| 总债务/股东权益 (D/E MRQ) | 35.65% |
| 流动比率 (MRQ) | 5.20 |
| 营业现金流 (OCF TTM) | -263.30 M |
| 杠杆自由现金流 (LFCF TTM) | -202.32 M |
| 资产报酬率 (ROA TTM) | -8.77% |
| 股东权益报酬率 (ROE TTM) | -20.00% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Legend Biotech Corporation | 看跌 | 看跌 |
AIStockmoo 评分
1.6
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.63 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 1.31% |
| 机构持股比例 | 47.92% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Westfield Capital Management Co Lp | 31 Dec 2025 | 6,164,677 |
| Hhlr Advisors, Ltd. | 31 Dec 2025 | 5,984,550 |
| Deerfield Management Company, L.P. | 31 Dec 2025 | 5,932,000 |
| Artisan Partners Limited Partnership | 31 Dec 2025 | 2,341,074 |
| Davern Capital Partners, Lp | 31 Dec 2025 | 1,056,668 |
| Matthews International Capital Management Llc | 31 Dec 2025 | 956,824 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 80.00 (Barclays, 321.72%) | 购买 |
| 中 | 58.00 (205.75%) | |
| 低 | 21.00 (TD Cowen, 10.70%) | 保留 |
| 平均值 | 58.00 (205.75%) | |
| 总计 | 7 购买, 1 保留 | |
| 平均价格@调整类型 | 21.42 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Barclays | 04 Feb 2026 | 80.00 (321.72%) | 购买 | 16.65 |
| HC Wainwright & Co. | 22 Jan 2026 | 50.00 (163.57%) | 购买 | 19.34 |
| TD Cowen | 22 Jan 2026 | 21.00 (10.70%) | 保留 | 19.34 |
| RBC Capital | 20 Jan 2026 | 66.00 (247.92%) | 购买 | 23.42 |
| Oppenheimer | 07 Jan 2026 | 75.00 (295.36%) | 购买 | 22.72 |
| Cantor Fitzgerald | 17 Dec 2025 | 74.00 (290.09%) | 购买 | 21.42 |
| Morgan Stanley | 12 Dec 2025 | 50.00 (163.57%) | 购买 | 22.32 |
| UBS | 08 Dec 2025 | 48.00 (153.03%) | 购买 | 26.12 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合